TY - JOUR T1 - Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3 JF - Anticancer Research JO - Anticancer Res SP - 81 LP - 89 DO - 10.21873/anticanres.14753 VL - 41 IS - 1 AU - MIYAKO SAGARA AU - SHOHEI MIYAMOTO AU - SHUN ITOH AU - YASUSHI SODA AU - KENZABURO TANI Y1 - 2021/01/01 UR - http://ar.iiarjournals.org/content/41/1/81.abstract N2 - Background/Aim: Breast cancer is the most common cancer in women worldwide, and triple-negative breast cancer (TNBC) is highly refractory to current standard therapies. Oncolytic virotherapy has recently gathered attention as a new treatment candidate for refractory cancers. Materials and Methods: We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers, and demonstrated that miRNA target sequence insertion into CVB3 reduced its pathogenicity, retaining its original oncolytic activity. In this study, we examined the oncolytic effects of CVB3 against breast cancer cells including TNBC cells. Results: CVB3 infection killed breast cancer cells in a time- and titer-dependent manner, and induced apoptosis. Nude mice transplanted with human TNBC cells were successfully treated with both CVB3-WT and CVB3-HP. Importantly, mice treated with CVB3-HP showed very few adverse events. Conclusion: CVB3-HP is a strong oncolytic virus candidate for breast cancer, including TNBC, due to its remarkable oncolytic efficacy and improved safety profile. ER -